Intravitreal triamcinolone acetonide in sympathetic ophthalmia.

Abstract

PURPOSE:

To report the result of intravitreal triamcinolone acetonide in the treatment of sympathetic ophthalmia.

METHODS:

A 29-year-old woman who suffered from sympathetic ophthalmia and who was being treated with systemic corticosteroid therapy received an intravitreal injection of 4 mg of triamcinolone acetonide.

RESULTS:

By the 15th day after injection visual acuity had improved from 20/200 to 20/40 and serous retinal detachment had almost completely resorbed. Systemic corticosteroid therapy was reduced sequentially. By the third month after injection, the patient was in clinical remission. Her visual acuity was 20/20 and no serous detachment was observed.

CONCLUSIONS:

In this study, short-term improvement in the clinical picture of a patient with sympathetic ophthalmia after intravitreal triamcinolone acetonide injection was described. The results suggest that intravitreal triamcinolone acetonide injection may be an additional tool in the treatment of sympathetic ophthalmia.

• Authors: Hakan Ozdemir, Murat Karacorlu, Serra Karacorlu
• Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (Graefes Arch Clin Exp Ophthalmol) Vol. 243 Issue 7 Pg. 734-6 (Jul 2005) ISSN: 0721-832X [Print] Germany
• PMID: 15756580 (Publication Type: Case Reports, Journal Article)

Chemical References

• Glucocorticoids
• Triamcinolone Acetonide

Topics

• Acute Disease
• Adult
• Female
• Fluorescein Angiography
• Glucocorticoids (therapeutic use)
• Humans
• Injections
• Ophthalmia, Sympathetic (drug therapy)
• Tomography, Optical Coherence
• Triamcinolone Acetonide (therapeutic use)
• Visual Acuity
• Vitreous Body